期刊文献+

尼妥珠单抗联合多西他赛-顺铂-氟尿嘧啶治疗晚期头颈鳞状细胞癌 被引量:6

Clinical research of therapeutic efficacy of nimotuzumab plus docetaxel-cisplatin-fluorouracil regimen as induction treatment of advanced head and neck squamous cell carcinoma
原文传递
导出
摘要 目的研究尼妥珠单抗联合多西他赛(TXT)+顺铂(DDP)+5-氟尿嘧啶(5-FU)方案(TPF方案)治疗晚期头颈部鳞状细胞癌(HNSCC)的临床疗效。方法将21例确诊为晚期HNSCC患者随机分成对照组和治疗组。对照组给予TPF化疗方案;治疗组在使用上述TPF化疗方案的同时,给予200 mg尼妥珠单抗静滴。治疗结束后评价疗效;并根据治疗前后患者生存质量评价(KPS)变化,评价患者生存质量;观察治疗过程中出现的副作用。结果在化疗治疗2个周期结束后的第4周进行评价,治疗组完全缓解(CR)3例、部分缓解(PR)7例、疾病稳定(SD)1例;对照组CR 1例、PR 3例、SD 2例,疾病进展(PD)4例。以CR+PR计算两组有效率、CR+PR+SD计算疾病控制率,比较差异均有统计学意义(P<0.05)。两组主要不良反应发生率差异无统计学意义(P>0.05)。KPS评分治疗组高于对照组。结论尼妥珠单抗联合TPF方案能进一步提高晚期HNSCC治疗效果及患者生存质量,且不增加不良反应,值得进一步研究及推广应用。 Objective To evaluate the therapeutic effect of combined nimotuzumab and TPF regimen in the treatment of advanced head and neck squamous cell carcinoma (HNSCC). Methods Twenty one cases of advanced HNSCC were divided into 2 groups, treatment group and control group. Cases in the control group were treated with docetaxel, cis-platinum and fluorouracil, called TPF regimen. Combination of nimotuzumab and TPF regimen was applied in the treatment group. In order to assess the efficacy of nimotuzumab, after 2 cycles, quality of life was evaluated through comparation of Karnofsky (KPS) score before and after chemotherapy; and toxic and adverse effects were observed. Results At the fourth week after 2 cycles, complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) were assessed in the two groups. In the treatment group, eases were analysed and the results were CR (3), PR (7) and SD (1). In the control group, the results were CR (1), PR (3), SD (2) and PD (4). The response rate (RR, CR+PR) and the disease control rate (DCR, CR + PR + SD) showed significant difference between the 2 groups (P 〈 0.05); but the incidence of toxic and adverse effects had no statistic significance (P 〉 0.05). The KPS score of treatment group was higher than control group. Conclusions For advanced head and neck squamous cell carcinoma, nimotuzumab plus TPF regimen as induction treatment is effective for improving thetherapeutic effect and the quality of life, the toxicities are well tolerable. The regimen is worthy of further research and application.
出处 《中华口腔医学研究杂志(电子版)》 CAS 2013年第6期26-29,共4页 Chinese Journal of Stomatological Research(Electronic Edition)
基金 徐州市社会发展科技基金(XZZD1017)
关键词 尼妥珠单抗 头颈部肿瘤 鳞状细胞 多西他赛 顺铂 氟尿嘧啶 化学治疗 临床疗效 Nimotuzumab Head and neck neoplasms Carcinoma,squamous cell Docetaxel Cisplatin Fluorouracil Chemotherapy Therapeutic efficacy
  • 相关文献

参考文献13

  • 1郭伟.晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J].口腔颌面外科杂志,2012,22(2):77-81. 被引量:12
  • 2张莹,何金生,洪涛.重组抗体药物研究进展及应用[J].中国生物工程杂志,2009,29(8):102-106. 被引量:15
  • 3杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1479
  • 4周际昌.实用肿瘤内科学[M]{H}北京:人民卫生出版社,200347.
  • 5潘宏铭;徐农.肿瘤内科疾病临床治疗与合理用药[M]{H}北京:科学技术文献出版社,2007574-585.
  • 6Dutta PR,Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy[J].{H}CANCER LETTERS,2007,(02):165-177.
  • 7Dietz A,Boehm A,Mozet C. Current aspects of targeted therapy in head and neck tumors[J].{H}European Archives of Oto-Rhino-Laryngology,2008,(Suppl 1):S3-12.
  • 8Soulieres D,Senzer NN,Vokes EE. Multicenter phaseⅡ study of erlo-tinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck[J].{H}Journal of Clinical Oncology,2004,(01):77-85.
  • 9Crombet-Ramos T,Rak J,Pérez R. Antiproliferative,antiangiogenic and proapoptotic activity of h-R3:A Humanized anti-EGFR antibody[J].{H}International Journal of Cancer,2002,(06):567-575.
  • 10Philip PA,Benedetti J,Corless CL. Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in petients with advanced pancreatic adenocarcinoma:Southwest Ontology Group-direceted intergroup trial S0205[J].{H}Journal of Clinical Oncology,2010,(22):3605-3610.

二级参考文献71

  • 1王树森,管忠震,向燕群,姜文奇,林桐榆,张力.表皮生长因子受体酪氨酸激酶抑制剂Gefitinib对鼻咽癌荷瘤裸鼠移植瘤生长作用的实验研究[J].癌症,2004,23(z1):1365-1369. 被引量:9
  • 2陈志南.基于抗体的中国生物制药产业化前景[J].中国医药生物技术,2007,2(1):2-5. 被引量:11
  • 3陈智伟,廖美琳,陈玉蓉,赵家美,张心敏,成柏君.WHO标准和RECIST标准评价肺癌化疗疗效的比较[J].循证医学,2004,4(2):83-84. 被引量:33
  • 4Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA, 1984, 81:6851 -6855.
  • 5沈倍奋,陈志南,刘民培.重组抗体.北京:科学出版社,2005.217-234.
  • 6Booy E P, Johar D, Maddika S,et al. Monoclonal and bispecific antibodies as novel therapeutics.
  • 7Hwang W Y, Foote J. Immunogenicity of engineered antibodies. Methods, 2005, 36 ( 1 ) :3 - 10.
  • 8Kashmiri S V, De Pascalis R, Gonzales N R, et al. SDR grafting a new approach to antibody humanization. Methods, 2005, 36 (1) :25 -34.
  • 9Clark M. Antibody humanization : a case of the ‘ Emperor' s new clothes' ? Immunol Today, 2000, 21 (8) :397 - 402.
  • 10Leonard J P, Coleman M, Ketas J C, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin' s lymphoma. Clin Cancer Res, 2004, 10 (16) : 5327 N5334.

共引文献1598

同被引文献50

  • 1SCHMITZ S,ANG K K,VERMORKEN J,et al.Targeted therapies for squamous cell carcinoma of the head and neck:current knowledge and future directions[J].Cancer Treat Rev,2014,40:390-404.
  • 2MOHER D,LIBERATI A,TETZLAFF J,et al.Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J].BMJ,2009,339:b2535-b2535.
  • 3JADAD A R,MOORE R A,CARROLL D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary[J]?Control Clin Trials,1996,17:1-12.
  • 4PARMAR M K,TORRI V,STEWART L.Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J].Stat Med,1998,17:2815-2834.
  • 5HIGGINS J P,THOMPSON S G,DEEKS J J,et al.Measuring inconsistency in meta-analyses[J].BMJ,2003,327:557-560.
  • 6DERSIMONIAN R,LAIRD N.Meta-analysis in clinical trials[J].Control Clin Trials,1986,7:177-188.
  • 7BONNER J A,HARARI P M,GIRALT J,et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck[J].N Engl J Med,2006,354:567-578.
  • 8BONNER J A,HARARI P M,GIRALT J,et al.Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer:5-year survival data from a phase 3randomised trial,and relation between cetuximab-induced rash and survival[J].Lancet Oncol,2010,11:21-28.
  • 9RAMAKRISHNAN M S,ESWARAIAH A,CROMBET T,et al.Nimotuzumab,apromising therapeutic monoclonal for treatment of tumors of epithelial origin[J].MAbs,2009,1:41-48.
  • 10REDDY B K,LOKESH V,VIDYASAGAR M S,et al.Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck:a randomized,open-label,phase IIb,5-year study in Indian patients[J].Oral Oncol,2014,50:498-505.

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部